Mitsuru Shinohara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8639035/publications.pdf

Version: 2024-02-01

34 papers	3,225 citations	218677 26 h-index	361022 35 g-index
38 all docs	38 docs citations	38 times ranked	5666 citing authors

#	Article	IF	Citations
1	Interaction Between APOE Genotype and Diabetes in Longevity. Journal of Alzheimer's Disease, 2021, 82, 719-726.	2.6	4
2	ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 128-144.	2.4	45
3	APOE2: protective mechanism and therapeutic implications for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 63.	10.8	110
4	Interaction between APOE genotype and diabetes in cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12006.	2.4	25
5	APOE2 is associated with longevity independent of Alzheimerâ€™s disease. ELife, 2020, 9, .	6.0	33
6	The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1128, 85-101.	1.6	18
7	Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimerâ€™s disease model. Nature Communications, 2019, 10, 1365.	12.8	217
8	5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway. International Journal of Molecular Sciences, 2019, 20, 1488.	4.1	14
9	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. Brain, 2019, 142, 1077-1092.	7.6	120
10	APOE4-mediated amyloid-Î² pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	8.2	96
11	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	12.8	100
12	Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice. Neurobiology of Aging, 2017, 53, 112-121.	3.1	26
13	APOE Îµ4/Îµ4 diminishes neurotrophic function of human iPSC-derived astrocytes. Human Molecular Genetics, 2017, 26, 2690-2700.	2.9	162
14	Bidirectional interactions between diabetes and Alzheimer's disease. Neurochemistry International, 2017, 108, 296-302.	3.8	82
15	Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. Journal of Lipid Research, 2017, 58, 1267-1281.	4.2	174
16	Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6962-E6971.	7.1	96
17	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-Î²42 in Alzheimerâ€™s disease. Brain, 2017, 140, 3301-3316.	7.6	14
18	APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Annals of Neurology, 2016, 79, 758-774.	5.3	77

#	Article	IF	Citations
19	ABCA7 Deficiency Accelerates Amyloid-Î² Generation and Alzheimer's Neuronal Pathology. Journal of Neuroscience, 2016, 36, 3848-3859.	3.6	109
20	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 225-234.	7.7	73
21	Apolipoprotein E lipoprotein particles inhibit amyloid-Î² uptake through cell surface heparan sulphate proteoglycan. Molecular Neurodegeneration, 2016, 11, 37.	10.8	45
22	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nature Neuroscience, 2016, 19, 668-677.	14.8	268
23	Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Experimental Neurology, 2016, 277, 1-9.	4.1	50
24	Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway. Journal of Biological Chemistry, 2015, 290, 14208-14217.	3.4	49
25	Possible modification of AlzheimerÃ¢â‚¬â„¢s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Frontiers in Aging Neuroscience, 2014, 6, 71.	3.4	43
26	Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway. Journal of Biological Chemistry, 2014, 289, 11282-11292.	3.4	62
27	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimerâ€™s disease. Brain, 2014, 137, 1533-1549.	7.6	100
28	Brain regional correlation of amyloid-Î² with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-Î² accumulation. Acta Neuropathologica, 2013, 125, 535-547.	7.7	51
29	Neuronal Clearance of Amyloid-Î² by Endocytic Receptor LRP1. Journal of Neuroscience, 2013, 33, 19276-19283.	3.6	206
30	What can we learn from regional vulnerability to amyloid-Î² accumulation in nondemented individuals?. Neurodegenerative Disease Management, 2013, 3, 187-189.	2.2	2
31	Dual Effects of Statins on AÃŸ Metabolism: Upregulation of the Degradation of APP-CTF and AÃŸ Clearance. Neurodegenerative Diseases, 2012, 10, 305-308.	1.4	12
32	LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-Î². Journal of Neuroscience, 2012, 32, 16458-16465.	3.6	174
33	Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and AÎ² deposition in an Alzheimer mouse model with diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7036-7041.	7.1	460
34	Reduction of Brain Î²-Amyloid (AÎ²) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and AÎ² Clearance. Journal of Biological Chemistry, 2010, 285, 22091-22102.	3.4	95